.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AG05_Rilpivirine.Rilpivirine .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AG05_Rilpivirine.Rilpivirine| name: | Rilpivirine |
| ATC code: | J05AG05 | route: | oral |
| n-compartments | 2 |
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of antiretroviral therapy for the treatment of HIV-1 infection in combination with other antiretroviral agents. It is approved for use in treatment-naïve adult patients with HIV-1 and is widely used in clinical practice.
Pharmacokinetic parameters reported in healthy adult subjects after oral administration.
Thoueille, P, et al., & Guidi, M (2024). Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV. Frontiers in pharmacology 15 1437400–None. DOI:10.3389/fphar.2024.1437400 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39619609
Neyens, M, et al., & Rossenu, S (2021). Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV. The Journal of antimicrobial chemotherapy 76(12) 3255–3262. DOI:10.1093/jac/dkab338 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34510179
Néant, N, et al., & Solas, C (2018). Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. European journal of clinical pharmacology 74(4) 473–481. DOI:10.1007/s00228-017-2405-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29374296